We have two leading R&D teams composed over 360 personnel who focus on developing innovative patent drugs and first-to-market generic drugs respectively. Our key research scientists on average have over 10 years of new drug development experience from their tenures at multinational pharmaceutical companies. We employ a market-driven approach to selecting research and development targets that have the potential for gaining widespread market acceptance or becoming the best-in-class among similar products. In total we have 70 drugs under various development stages, including 14 innovative patented drugs.
In addition, we collaborate with leading research institutions, universities, and hospitals to further broaden our access to proprietary products, and minimize the costs and risks associated with early-stage development. Our investment on R&D has been well above the domestic average and accounted for about 6% to 10% of sales since 2007.
We believe that the development and launch of proprietary products are important to our sustainable growth and future success.